Search Results - "Jain, Preetesh"

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management by Jain, Preetesh, Wang, Michael

“…Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the…”
Get full text

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments by Jain, Preetesh, Wang, Michael L.

“…The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer…”
Get full text

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes by Kadia, Tapan M., Jain, Preetesh, Ravandi, Farhad, Garcia‐Manero, Guillermo, Andreef, Michael, Takahashi, Koichi, Borthakur, Gautam, Jabbour, Elias, Konopleva, Marina, Daver, Naval G., Dinardo, Courtney, Pierce, Sherry, Kanagal‐Shamanna, Rashmi, Patel, Keyur, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop M.

“…BACKGROUND Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in patients with acute myeloid leukemia (AML). METHODS Peripheral blood or…”
Get full text

Advances in the assessment of minimal residual disease in mantle cell lymphoma by Jung, Dayoung, Jain, Preetesh, Yao, Yixin, Wang, Michael

“…The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among…”
Get full text

Zanubrutinib in lymphoproliferative disorders: a comprehensive review by Muñoz, Javier, Wang, Yucai, Jain, Preetesh, Wang, Michael

“…The availability of Bruton tyrosine kinase (BTK) inhibitors has brought about a paradigm shift in the treatment of patients with B-cell lymphomas and chronic…”
Get full text

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy? by Beitinjaneh, Amer, Kaufman, Adrienne, Wang, Yucai, Jain, Preetesh, Srour, Samer A, Wang, Michael

“…Opinion statement For years, upfront autologous hematopoietic cell transplant (auto-HCT) has been the standard of care for younger and physically fit mantle…”
Get full text

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma by Jiang, Vivian Changying, Hao, Dapeng, Jain, Preetesh, Li, Yijing, Cai, Qingsong, Yao, Yixin, Nie, Lei, Liu, Yang, Jin, Jingling, Wang, Wei, Lee, Heng-Huan, Che, Yuxuan, Dai, Enyu, Han, Guangchun, Wang, Ruiping, Rai, Kunal, Futreal, Andrew, Flowers, Christopher, Wang, Linghua, Wang, Michael

“…Abstract Background Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell…”
Get full text

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma by Wang, Lifu, Tang, Guilin, Medeiros, L Jeffrey, Xu, Jie, Huang, Wenting, Yin, Cameron C, Wang, Michael, Jain, Preetesh, Lin, Pei, Li, Shaoying

“…Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in…”
Get full text

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis by Hill, Holly A., Qi, Xinyue, Jain, Preetesh, Nomie, Krystle, Wang, Yucai, Zhou, Shouhao, Wang, Michael L.

“…Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. Molecular aberrations in…”
Get full text

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia by Jain, Preetesh, Keating, Michael J, Wierda, William G, Sivina, Mariela, Thompson, Philip A, Ferrajoli, Alessandra, Estrov, Zeev, Kantarjian, Hagop, O'Brien, Susan, Burger, Jan A

“…Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients with del17p…”
Get full text

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials by Sasaki, Koji, MD, Strom, Sara S, PhD, O'Brien, Susan, Prof, Jabbour, Elias, MD, Ravandi, Farhad, Prof, Konopleva, Marina, MD, Borthakur, Gautam, MD, Pemmaraju, Naveen, MD, Daver, Naval, MD, Jain, Preetesh, MD, Pierce, Sherry, BSN, Kantarjian, Hagop, Prof, Cortes, Jorge E, Dr Prof

“…Summary Background Tyrosine-kinase inhibitors improve overall survival in patients with chronic myeloid leukaemia in chronic phase (CML-CP). Survival compared…”
Get full text

Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis by Jain, Preetesh, Kantarjian, Hagop, Cortes, Jorge

“…Opinion statement Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in the therapy of patients with chronic myeloid leukemia (CML) is…”
Get full text

Smudge cells in CD200 + , TP53 mutated leukemic mantle cell lymphoma by Jain, Preetesh, Han, Xin, Wang, Michael, Tang, Guilin

“…KCI Citation Count: 0…”
Get full text

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors by Le Gouill, Steven, Długosz-Danecka, Monika, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Smith, Stephen D, Doorduijn, Jeanette K, Panizo, Carlos, Shah, Bijal D, Davies, Andrew J, Eek, Richard, Jacobsen, Eric, Kater, Arnon P, Robak, Tadeusz, Jain, Preetesh, Calvo, Roser, Tao, Lin, Wang, Michael

Get full text

Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma by Zhang, Shaojun, Jiang, Vivian Changying, Han, Guangchun, Hao, Dapeng, Lian, Junwei, Liu, Yang, Cai, Qingsong, Zhang, Rongjia, McIntosh, Joseph, Wang, Ruiping, Dang, Minghao, Dai, Enyu, Wang, Yuanxin, Santos, David, Badillo, Maria, Leeming, Angela, Chen, Zhihong, Hartig, Kimberly, Bigcal, John, Zhou, Jia, Kanagal-Shamanna, Rashmi, Ok, Chi Young, Lee, Hun, Steiner, Raphael E., Zhang, Jianhua, Song, Xingzhi, Nair, Ranjit, Ahmed, Sairah, Rodriquez, Alma, Thirumurthi, Selvi, Jain, Preetesh, Wagner-Bartak, Nicolaus, Hill, Holly, Nomie, Krystle, Flowers, Christopher, Futreal, Andrew, Wang, Linghua, Wang, Michael

Get full text

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells by Rozovski, Uri, Grgurevic, Srdana, Bueso-Ramos, Carlos, Harris, David M, Li, Ping, Liu, Zhiming, Wu, Ji Yuan, Jain, Preetesh, Wierda, William, Burger, Jan, O'Brien, Susan, Jain, Nitin, Ferrajoli, Alessandra, Keating, Michael J, Estrov, Zeev

“…While reviewing chronic lymphocytic leukemia (CLL) bone marrow slides, we identified cytoplasmic lipid vacuoles in CLL cells but not in normal B cells. Because…”
Get full text

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs by Jain, Preetesh, Kantarjian, Hagop, Boddu, Prajwal C., Nogueras-González, Graciela M., Verstovsek, Srdan, Garcia-Manero, Guillermo, Borthakur, Gautam, Sasaki, Koji, Kadia, Tapan M., Sam, Princy, Ahaneku, Hycienth, O'Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Jabbour, Elias, Cortes, Jorge E.

“…Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase…”
Get full text

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins by Li, Yijing, Lee, Heng-Huan, Jiang, Vivian Changying, Che, Yuxuan, McIntosh, Joseph, Jordan, Alexa, Vargas, Jovanny, Zhang, Tianci, Yan, Fangfang, Simmons, Margaret Elizabeth, Wang, Wei, Nie, Lei, Yao, Yixin, Jain, Preetesh, Wang, Michael, Liu, Yang

“…Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but…”
Get full text

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma by Martinez-Baquero, Diana, Sakhdari, Ali, Mo, Huan, Kim, Do Hwan, Kanagal-Shamanna, Rashmi, Li, Shaoying, Young, Ken H., O’Malley, Dennis P., Dogan, Ahmet, Jain, Preetesh, Wang, Michael L., McDonnell, Timothy J., Miranda, Roberto N., Vega, Francisco, Medeiros, L. Jeffrey, Ok, Chi Young

“…Enhancer of zeste homolog 2 (EZH2) is a catalytic component of the polycomb repressive complex 2 (PRC2) which reduces gene expression via trimethylation of a…”
Get full text

Recent advances in de novo CD5+ diffuse large B cell lymphoma by Jain, Preetesh, Fayad, Luis E., Rosenwald, Andreas, Young, Ken H., O'Brien, Susan

“…Various subsets of DLBCL are distinguished based on molecular and immunohistochemical features. CD5 expressing DLBCL (CD5+ DLBCL) is increasingly recognized as…”
Get full text